RVMDW: Bull Flag detected on 1 Jul 2026

Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for RAS-addicted cancers, and the warrant (RVMDW) is forming a bull flag pattern with strong technical merit. The structure score of 15.0/15 indicates a textbook consolidation forming above key support at $4.70, with current price at $9.38 just below resistance at $7.29. The breakout score (12.1/13) and overall quality score (81.1/98) suggest high-probability setup. Volume is moderately below average (82% of 20-day mean), which could intensify on a decisive breakout above $7.29. RSI at 72.74 signals overbought conditions requiring validation from volume.

In May 2026, Revolution Medicines reported positive results from the RASolute 302 trial of daraxonrasib, demonstrating unprecedented improvement in overall survival in previously treated metastatic pancreatic cancer. The data showed daraxonrasib nearly doubling median overall survival versus chemotherapy. Sixteen analysts have issued price targets in the last 6 months, with a median target of $170, indicating substantial conviction. On July 1–4, 2026, the company is presenting RAS(ON) pipeline data at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich. However, insider trading over the past 6 months shows 43 sales and 0 purchases among executives, creating a headwind despite strong clinical momentum.

The RASolute 302 results mark a major advance that Revolution Medicines intends to submit to global health authorities as part of a New Drug Application to the FDA under the Commissioner's National Priority Voucher program. A successful breakout would clear resistance at $7.29 with volume exceeding the 80,632 20-day average, targeting the conservative measure of $9.69—a 30% gain from consolidation base. The win probability score of 70.98% reflects favorable odds, though invalidation occurs decisively below $4.70. Volume confirmation is critical given the 82% relative volume; sustained breakout requires institutional accumulation.

RSI at 72.74 indicates overbought extremes—warrant volatility (atr_pct: 8.1%) and beta of 2.03 amplify downside swings during profit-taking. Steve Kelsey, M.D., president of R&D, transitions to senior advisor on July 1, 2026, and retires January 4, 2027—a material R&D leadership change during critical regulatory phases. Biotech regulatory risk remains: clinical trial delays, manufacturing challenges, or FDA scrutiny could derail the daraxonrasib NDA timeline. The warrant expires December 17, 2026—only 5.5 months from detection date, creating compressed time for monetization before decay acceleration.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.